Tags : IBD

PharmaShots Interview: CTMA’ Dr. Pierre Pellier Shares Insight on CT-SCOUT

Tuba Khan October 12, 2021

In an interview with PharmaShots, Dr. Pierre Pellier, CEO of CTMA, share his views on CT-SCOUT that helps to boost patient recruitment in the clinical trials for IBD Shots: CTMA […]readmore

Biosimilars Clinical Trials

Samsung Bioepis Reports Results of Renflexis (biosimilar, infliximab) from Two

Tuba Khan October 27, 2020

Shots: The company reported results from two real-world studies of Renflexis (infliximab-abda) in patients with IBD registered in the US Veteran Affairs Healthcare System database. Data were presented at ACG […]readmore

Tags : IBD

PharmaShots Interview: CTMA’ Dr. Pierre Pellier Shares Insight on CT-SCOUT

Samsung Bioepis Reports Results of Renflexis (biosimilar, infliximab) from Two

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : IBD

PharmaShots Interview: CTMA’ Dr. Pierre Pellier Shares Insight on CT-SCOUT

Samsung Bioepis Reports Results of Renflexis (biosimilar, infliximab) from Two

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company